Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 26 of 47 for:    Venetoclax AND cell lymphoma

Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03955783
Recruitment Status : Recruiting
First Posted : May 20, 2019
Last Update Posted : July 1, 2019
Sponsor:
Collaborators:
Karyopharm Therapeutics Inc
AbbVie
Information provided by (Responsible Party):
Michael Byrne, Vanderbilt-Ingram Cancer Center

Brief Summary:
This phase Ib trial studies the toxicity and dosing of venetoclax in combination with selinexor, and how well the combination works in treatment of patients with high risk hematologic malignancies such as diffuse large B-cell lymphoma and acute myeloid leukemia that has come back (recurrent) or does not respond to initial treatment (refractory). Venetoclax functions by inhibiting a protein in the body called bcl-2, which is involved in slowing down the normal process by which old cells in the body are cleared (called apoptosis). Selinexor functions by trapping "tumor suppressing proteins" within the cell and causing the cancer cells to die or stop growing. This study examines the effects, if any, of selinexor and venetoclax on high risk hematologic malignancies and on the body, including any side-effects.

Condition or disease Intervention/treatment Phase
Diffuse Large B-cell Lymphoma Acute Myeloid Leukemia Non-Hodgkin's Lymphoma Drug: Venetoclax Drug: Selinexor Phase 1

Detailed Description:

Primary:

  • Escalation: Identify the maximum tolerated dose(s) (MTD) and recommended phase 2 dose(s) (RP2D) of SEL-VEN combination therapy in patients with diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML).
  • Expansion: Determine the overall response rate of SEL-VEN combination therapy in patients with relapsed/refractory hematologic malignancies.

Exploratory Objectives:

  • To explore biomarkers of response to SEL-VEN therapy.
  • To determine the progression free survival (PFS) and overall survival (OS) of SEL-VEN combination therapy.

OUTLINE: This is a dose-escalation study.

Patients receive venetoclax orally (PO) once daily (QD) on days 1-28. Patients with DLBCL receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Patients with venetoclax-naive AML are treated with selinexor on days 8, 15, and 22 of cycle 1, followed by days 1, 8, 15, and 22 of subsequent cycles. Venetoclax-refractory AML patients begin both drugs on cycle 1 day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 28 days and every 3 months for 2 years.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 78 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Investigator-Sponsored Phase Ib Trial of Venetoclax and SINE: Selective Inhibition of Nuclear Export in Patients With High Risk Hematologic Malignancies
Actual Study Start Date : June 21, 2019
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2022


Arm Intervention/treatment
Experimental: Treatment (venetoclax, selinexor)
Patients receive venetoclax PO QD on days 1-28. Patients with DLBCL receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Venetoclax naïve AML patients receive selinexor on days 8, 15, and 22 of cycle 1, followed by days 1, 8, 15, and 22 of subsequent cycles. Venetoclax refractory AML patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Venetoclax
Given by mouth

Drug: Selinexor
Given by mouth




Primary Outcome Measures :
  1. Maximum tolerated dose (escalation) [ Time Frame: Up to 28 days ]
  2. Overall response rate (expansion) [ Time Frame: At 12 weeks ]

Secondary Outcome Measures :
  1. Progression free survival [ Time Frame: Up to 2 years ]
    Will be estimated using the Kaplan-Meier method with 95% confidence intervals. Descriptive statistics will be used to summarize survival outcomes among subgroups. Will be compared with historical controls of patients that received venetoclax monotherapy

  2. Overall survival [ Time Frame: Up to 2 years ]
    Will be estimated using the Kaplan-Meier method with 95% confidence intervals. Descriptive statistics will be used to summarize survival outcomes among subgroups. Will be compared with historical controls of patients that received venetoclax monotherapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.
  • Age ≥ 18 years
  • Life expectancy > 12 weeks.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically confirmed diagnosis of one of the following, in accordance with WHO diagnostic criteria:

    • Escalation:
    • Diffuse Large B-cell Lymphoma (DLBCL, including primary mediastinal large B cell lymphoma, T cell rich B cell lymphoma, and high-grade B cell lymphoma NOS). Patients with Burkitt's, lymphoblastic lymphoma, follicular lymphoma, and mantle cell lymphoma are not included. OR
    • Acute Myeloid Leukemia (AML)
    • Expansion:
    • Diffuse Large B-cell Lymphoma and acute myeloid leukemia as above.
    • VEN Refractory expansion cohort: Patients must have previously received and failed venetoclax therapy (either monotherapy or combination) during their treatment course (i.e., patients may receive non-VEN therapy immediately prior to enrollment on this study). Treatment failure is defined as evidence of disease progression after ≥ 1 cycle (four weeks) of full-intensity venetoclax-based therapy (i.e., 28 days exclusive of ramp-up. Patients that require dose reductions due to intolerance may be considered for this cohort after discussion with the sponsor.)
    • Patients with CLL/SLL and Mantle Cell Lymphoma are excluded from the VEN Refractory cohort.
  • Relapsed or refractory following ≥ 1 line(s) of prior therapy and subjects are refractory to, intolerant of, or ineligible for therapies known to provide clinical benefit.
  • Patients that relapse ≥ 3 months after allogeneic hematopoietic cell transplantation (HCT) are eligible.
  • Female patients of childbearing potential must agree to use two methods of contraception (including one highly effective and one effective method of contraception) and have a negative serum pregnancy test at Screening. Male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential. For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose of study treatment.
  • For leukemia and DLBCL with known or suspected marrow involvement, patients must have at least 10-15 mL of bone marrow aspirate material obtained within 14 days of beginning treatment on this study. Patients with DLBCL must have 3-5 unstained slides, or tissue block, available for evaluation within 14 days of study enrollment in the expansion cohorts. DLBCL patients enrolled during the escalation phase must have blocks available for submission within 28 days of beginning treatment.
  • CBC testing must confirm adequate marrow reserve, as demonstrated by:

    • DLBCL: Hgb ≥ 10g/dL, platelets ≥ 75,000 cells/mm3 , ANC ≥ 1,000 cells/mm3
  • Adequate organ function, as demonstrated by:

    • Total bilirubin < 1.5 x upper limit of normal (ULN) (except patients with Gilbert's syndrome (hereditary indirect hyperbilirubinemia), who must have a total bilirubin of < 3 x ULN, and
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) normal to < 2 x ULN
    • Calculated creatinine clearance > 50 mL/min (per the Cockcroft-Gault formula).

Exclusion Criteria:

  • Patients who are pregnant or lactating
  • Patients who received any systemic anticancer therapy including investigational agents or radiation ≤3 weeks (or ≤5 half-lives of the drug [whichever is shorter]) prior to C1D1. Hydroxyurea is permitted for up to 14 days in AML patients
  • Inadequate recovery from toxicity attributed to prior anti-cancer therapy. With the exception of alopecia or fatigue, patients must have recovered to baseline or ≤ Grade 1 (NCI-CTCAE v4.03) residual toxicity prior to first dose of protocol-indicated treatment.
  • Participation in another clinical trial with any investigational drug within 14 days prior to study enrollment.
  • Patients included in the VEN refractory cohort that have discontinued venetoclax therapy (either monotherapy or combination) due to toxicity or hypersensitivity, including prior history of grade 3/4 TLS during prior VEN exposure
  • In dose expansion cohorts, except venetoclax relapsed cohort, no prior treatment with SINE compounds, another XPO1 inhibitor, or BCL-2 inhibitors.
  • Active GVHD requiring calcineurin inhibitors or steroid dosing ≥ 10mg/day prednisone (or equivalent) or < 3 months from allogenic hematopoietic stem cell transplant (HSCT).
  • Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; however, prophylactic use of these agents is acceptable even if parenteral.
  • Major surgery within 2 weeks of first dose of study drug.
  • Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety.
  • Unstable cardiovascular function:

    • Symptomatic ischemia, or
    • Uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on anti-arrhythmia therapy are excluded; 1st degree AV block or asymptomatic LAFB/RBBB will not be excluded), or
    • Congestive heart failure (CHF) of NYHA Class ≥3, or
    • Myocardial infarction (MI) within 3 months.
  • Known active Hepatitis B or Hepatitis C infection (Hepatitis testing is not required as part of this study).
  • Known human immunodeficiency virus (HIV) infection (HIV testing is not required as part of this study).
  • Subject has received the following ≤ 7 days prior to Cycle 1, Day 1: Strong and moderate CYP3A inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort.
  • Subject has received the following ≤ 5 days prior to Cycle 1, Day 1: Strong and moderate CYP3A inhibitors such as fluconazole, ketoconazole, and clarithromycin.
  • Subject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit ≤ 3 days prior to Cycle 1, Day 1.
  • Inability to swallow oral medication; or the presence of a poorly controlled gastrointestinal disease, disorder, syndrome, or dysfunction that could significantly affect the absorption of oral study drug - e.g. Crohn's disease, ulcerative colitis, chronic diarrhea (defined as > 4 loose stools per day), malabsorption syndrome, or bowel obstruction.
  • Inability or unwillingness to take required and recommended medications intended to prevent and treat potential adverse events of tumor lysis syndrome (TLS), nausea and vomiting (e.g. 8 mg ondansetron or equivalent), loss of appetite, and fatigue.
  • Patients unwilling to comply with the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03955783


Contacts
Layout table for location contacts
Contact: Vanderbilt-Ingram Service Information Program 800-811-8480 cip@vumc.org

Locations
Layout table for location information
United States, Tennessee
Vanderbilt-Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Vanderbilt-Ingram Service Information Program    800-811-8480    cip@vumc.org   
Principal Investigator: Michael Byrne, DO         
Sponsors and Collaborators
Michael Byrne
Karyopharm Therapeutics Inc
AbbVie
Investigators
Layout table for investigator information
Principal Investigator: Michael Byrne, DO Vanderbilt Medical Center

Layout table for additonal information
Responsible Party: Michael Byrne, Sponsor Investigator, Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov Identifier: NCT03955783     History of Changes
Other Study ID Numbers: VICC HEM 1755
NCI-2019-02953 ( Registry Identifier: NCI, Clinical Trials Reporting Program )
First Posted: May 20, 2019    Key Record Dates
Last Update Posted: July 1, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Venetoclax
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents